Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting

World News: . []

RICHLAND, Wash., June 12, 2019 (GLOBE NEWSWIRE) --   (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will launch  campaign introducing a new look and feel for the Cesium product group at the American Brachytherapy Society’s (ABS) annual meeting. The ABS 2019 annual meeting will be held June 13-15 at the InterContinental Miami hotel in Miami, Florida. 

The initiative introduces the new brand identity for Isoray’s innovative product offerings and focuses on raising awareness of the important advances in the treatment of cancers utilizing brachytherapy powered by Cesium-131, now known as Cesium Blu™. It delivers a precisely targeted dosage to a tumor as it aggressively attacks the cancer being treated. Patients see an improved quality of life from less damage to the surrounding tissue and organs, the side effects that resolve more quickly, and the decreased required radiation time compared to other options. Cesium Blu can be an effective treatment for patients with prostate cancer as well as many difficult to treat cancers including brain, pelvic, gyn, head and neck, lung and colorectal cancers. Isoray CEO Lori Woods said the introduction of the new brand identity with the launch of campaign is an important step forward. “The word Cesium comes from the Latin word for blue and blue is the light wave emitted from Cesium. Its purity and power are reflected in our new look and feel allowing us to further evolve our brand identity and distinguish our innovative, standout brachytherapy treatment, Cesium Blu, and our growing family of powerful products. It underscores the strategic turn in our direction as we focus on the continued growth of awareness and adoption.” Woods said the annual ABS gathering will be particularly noteworthy. “We have so much to share with attendees this year. I welcome this opportunity to discuss our new efforts including our customized, real-time surgical delivery device, Blu Build™, and our powering of GammaTile™ Therapy, treating brain cancers using Cesium Blu, which are great indicators of our progress. We see the ABS meeting as the perfect occasion to unveil our new brand identity and discuss the growing applications of Cesium Blu and the significant benefits it provides patients.” Isoray representatives will be at Booth #14 to discuss recent developments with attendees. The company will also be hosting two special events offering additional opportunities to learn about at the Bluewater Rooftop Restaurant at the ABS meeting host hotel, the InterContinental Miami.  “” is scheduled for Thursday, June 13 at 9:00 p.m. and is scheduled for Friday, June 14 from 6:00 p.m. - 8:00 p.m.

Media and Public Relations: Sharon Schultz (302) 539-3747
Investor Relations: Mark Levin (501) 255-1910

More news and information about IsoRay, Inc.

Published By:

Globe Newswire: 13:13 GMT Wednesday 12th June 2019

Published: .

Search for other references to "isoray" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us